comparemela.com

Latest Breaking News On - Jonathan david schwartz - Page 1 : comparemela.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Releases Quarterly Earnings Results, Beats Expectations By $0 11 EPS

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.11, Briefing.com reports. During the same period last year, the company earned ($0.67) earnings per share. Rocket Pharmaceuticals Price Performance Shares of RCKT stock […]

Chardan Capital Trims Rocket Pharmaceuticals (NASDAQ:RCKT) Target Price to $61 00

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) had its price objective lowered by Chardan Capital from $63.00 to $61.00 in a research report issued to clients and investors on Friday, The Fly reports. Chardan Capital’s price target indicates a potential upside of 190.48% from the company’s previous close. A number of other research firms have also […]

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded at StockNews com

StockNews.com upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) to a sell rating in a research report report published on Wednesday morning. A number of other equities analysts have also issued reports on RCKT. Morgan Stanley assumed coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, February 1st. They set an […]

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded at StockNews com

StockNews.com upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) to a sell rating in a report released on Wednesday. A number of other equities research analysts have also weighed in on the stock. William Blair reiterated an outperform rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, March 22nd. Needham & […]

Rocket Pharmaceuticals (NASDAQ:RCKT) Given Buy Rating at Needham & Company LLC

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $60.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s target price would suggest a potential upside of […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.